Premium
P1‐359: Discovery and identification of plasma biomarkers in Alzheimer's dementia diagnostics
Author(s) -
Manral Pallavi,
Tripathi Manjari,
Singh Tej P.,
Srinivasan Alagiri
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.941
Subject(s) - dementia , alzheimer's disease , medicine , population , disease , oncology , bioinformatics , biology , environmental health
yielded a proportional decrease of alpha-synuclein levels, and in healthy individuals, measured concentrations were within a narrow range. In addition, compared to monomer, equimolar oligomeric alpha-synuclein preparations showed no decreased protein concentration, which has been observed in ELISAs measuring amyloid-beta. Conclusions: This ELISA seems to be a valuable tool for the accurate measurement of small concentration differences of total human alpha-synuclein in plasma and CSF. This is a prerequisite for exploring alpha-synuclein as a potential biomarker for neurodegenerative diseases as well as for monitoring protein levels in disease-modifying treatment approaches targeting alpha-synuclein. In addition, this ELISA might be useful to assess the potential preclinical risk profile for a developing synucleinopathy in previously unaffected individuals.